Live feed08:05:00·36dNEWSReleaseProtagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque PsoriasisPTGX· Protagonist Therapeutics Inc.Health CareOriginal source
